CD274 and cancer: Similar results were described on the basis of only exome sequencing data for lung cancer patients with anti-PD1 responses65, for bladder cancer and other high mutational load cancers with anti-PD-L1 responses66,67, and recently for MMR-deficient colon and other MMR-deficient cancers treated with anti-PD1 therapy68.